Multikinase inhibitors use in differentiated thyroid carcinoma

Describes newly developed small-molecule tyrosine kinase inhibitors (TKI) that are being actively tested and used in the management of advanced differentiated thyroid cancer (DTC). Looks at traditional treatment of DTC involving surgery, radioactive iodine, or cytotoxic chemotherapy, then summarises the clinical experience reported for the important TKIs that are being tested or have potential for use in DTC : Sorafenib, Sunitinib, Motesanib, Axitinib, Pazopanib, Lenvatinib, BRAF inhibitors, MEK inhibitors, mTOR inhibitors, and TKI combination therapies. Overviews TKI-related side effects. Offers recommendations for patients who are considering or already using TKIs. Source: National Library of New Zealand Te Puna Matauranga o Aotearoa, licensed by the Department of Internal Affairs for re-use under the Creative Commons Attribution 3.0 New Zealand Licence.